Plazinemdor

DB21493InvestigationalSmall molecule

Plazinemdor is a small molecule drug. Plazinemdor is under investigation in clinical trial NCT04306146 (Study of CAD-9303 in Subjects With Schizophrenia). Plazinemdor has a monoisotopic molecular weight of 432.12 Da.

Chemical structure of Plazinemdor
Formula / weight
C21H19ClF2N4O2 · 432.86 g/mol (avg)
Code names
CAD-9303

Resolves to

Compound
UNIIS0CE8P9OKWCAS2378285-59-5ChEMBLCHEMBL6166025
Structure
InChIKeyNULHGWQIRTXKAY-UHFFFAOYSA-NSMILESCC1(F)CN(C1)C(=O)CN1C=NC2=C(C(=CN2C2CC2)C2=CC(Cl)=C(F)C=C2)C1=O

What you can answer from here — as of August 31, 2026

1Clinical trialPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of Plazinemdor, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In